Publicaciones
-
Río P, Zubicaray J, Navarro S, Gálvez E, Sánchez-Domínguez R, Nicoletti E, Sebastián E, Rothe M, Pujol R, Bogliolo M, John-Neek P, Bastone AL, Schambach A, Wang W, Schmidt M, Larcher L, Segovia JC, Yáñez RM, Alberquilla O, Díez B, Fernández-García M, García-García L, Ramírez M, Galy A, Lefrere F, Cavazzana M, Leblanc T, García de Andoin N, López-Almaraz R, Català-Temprano A, Barquinero J, Rodríguez-Perales S, Rao G, Surrallés J, Soulier J, Díaz-de-Heredia C, Schwartz JD, Sevilla J and Bueren JA.
Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials.
Lancet . 404(10471): 2584-2592. Nº de citas: 13
-
Rey-Barroso L, Roldan-Molina M, Frías M, Burgos-Fernández FJ, Isola I, Ruiz-Llobet A, Sarrate E and Vilaseca M.
Optimized protocol for intracellular labeling of red blood cells with anti-hemoglobin F for confocal microscopy analysis.
MICRON . 199: 103913-103913.
-
Fuentes P, García-Peydró M, Alcain J, Mosquera M, Cela C, Cifuentes C, Torrebadell-Burriel M, Isola I, Camós-Guijosa M, Ramírez M, Alarcón B and Toribio ML.
Pre-TCR-targeted immunotherapy for T cell acute lymphoblastic leukemia.
NATURE IMMUNOLOGY . 26(10): 1712-1725. Nº de citas: 2
-
Iriondo J, Zubicaray J, Río P, Català-Temprano A, Solsona M, Sanz A, Gómez A, Sebastián E, de la Cruz A, Galán A, Navarro S, Larcher L, de Andoin NG, Uriz JJ, Vagace JM, Gonzalez de Pablo J, Pujol MR, Nicoletti E, Surrallés J, Martín-Prado S, Schwartz JD, Soulier J, Bueren JA and Sevilla J.
Eltrombopag for Bone Marrow Failure in Fanconi Anemia: Results From the Phase II Clinical Trial FANCREV.
EUROPEAN JOURNAL OF HAEMATOLOGY . 115(4): 403-412.
-
Bartoló-Ibars A, Aran A, Johansson AM, Ortiz-Maldonado V, Klein-González N, Alonso-Saladrigues A, James E, Urbano-Ispizua A, Rives-Solà S, Delgado J, González-Navarro EA, Kwok WW and Juan-Otero M.
T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes.
Journal for ImmunoTherapy of Cancer . 13(9): .
-
Romero-Moya D, Torralba-Sales E, Calvo C, Marin-Bejar O, Magallon-Mosella M, Distefano-Muñoz ME, Pera J, Juan Castaños Asins, De Giorgio F, Gonzalez J, Iglesias A, Berenguer-Balaguer C, Schilling M, Plass M, Pasquali L, Català-Temprano A, Molina O, Wlodarski MW, Bigas A and Giorgetti A.
CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness
Leukemia . : .
-
Awasthi R, Grupp SA, Waldron E, Yanik GA, Tam CS, Rives-Solà S, McGuirk JP, Pulsipher MA, Jaeger U, Myers GD, Borchmann P, Schuster SJ, Stefanski HE, Bishop MR, Chakraborty A, Masood A, Baruchel A and Waller EK.
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL
blood advances . 9(17): 4405-4414.
-
Cesaro, S, Verheggen, I, Tridello, G, Styczynski, J, Roeven, WHM, Hwang, A, Stamouli, M, Petrov, Y, Ben Abdeljelil, N, Mazilier, P, Zaidman, I, Tambaro, FP, Elias, S, Verna, M, Marsal-Ricoma J, Karas, M, Corral, LL, Goussetis, E, Cerretti, R, Perruccio, K, Hornakova, M, Wölfl, M, Nordlander, A, Biffi, A, Spadea, M, Salinas, AS, Bramanti, S, Belendez, C, Skert, C, Gozdzik, J, Cuoghi, A, Mas, MH, Pennisi, M, de Becker, A, Richardson, D, Peric, Z, de la Camara, R and Averbuch, D.
A survey on the practices and the management of hemorrhagic cystitis in patients who undergo allogeneic hematopoietic stem cell transplantation, on behalf of the Infectious Diseases Working Party of EBMT
BONE MARROW TRANSPLANTATION . : .
-
Silbert SK, Rankin AW, Hoang CN, Semchenkova A, Myers RM, Zerkalenkova E PhD, Wang HW, Kovach AE, Yuan CM, Delgado Colon D, Vasseur L, Bataller A, John S, Utley Lyons K, Friedes BD, Alonso-Saladrigues A, Abdel-Azim H, Balducci E, Aljudi A, Balsat M, Biery DN, Chamdin A, Chang BH, Cuevo RS MD, De Moerloose B, Dickens DS, Duffner UA, Duployez N, El Chaer F, Elliott MA, Escherich G, Fernandes S, Fitzjohn MR, Gahvari ZJ, Grupp SA, He RR MD, Harrison C, Hergott CB, Hsieh EM, Kim AS, Kuo DJ, Larson DP, Lee BJ, Leguay TT, Lindsley RC, Mangaonkar AA, Mezger K, Pacenta HL, Pan J, Provost MRM, Puri L, Raikar SS, Martinez AJ, Bristol IQ, Murphy KD, Reiman L, Redell MS, Reed K, Roth Guepin G, Rubinstein JD, Savasan S, Schafernak KT, McLean Stevens A, Talleur AC, Torres Carapia N, Vargaftig J, Vatsayan A, Wölfl M, Zhao L, Rives-Solà S, Fabrizio VA, Sasaki K, Aldoss I, Boissel N, Rheingold SR, Davis KL, Ghorashian S, Jacoby E, Popov A, Lamble AJ and Shah NN.
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
Blood . 146(4): 437-455. Nº de citas: 3
-
Kotmayer L, Kozyra EJ, Kang G, Strahm B, Yoshimi A, Sahoo SS, Pastor VB, Attardi E, Voss R, Vinci L, Kaiser M, Dworzak MN, De Moerloose B, Sukova M, Starý J, Hasle H, Jahnukainen K, Polychronopoulou S, Kállay K, Smith OP, Malone A, Barzilai Birenboim S, Masetti R, Buechner J, Ussowicz M, Kjöllerström P, Bodova I, Kavcic M, Català-Temprano A, Turkiewicz D, Schmugge M, de Haas V, Okhomina VI, Sotomayor C, Catalán P, Wehr C, Salzer U, Germing U, Gattermann N, Bödör C, Gray N, Lewis S, Shimamura A, Giorgetti A, Erlacher M, Niemeyer CM and Wlodarski MW.
Age-dependent phenotypic and molecular evolution of pediatric MDS arising from GATA2 deficiency.
BLOOD CANCER JOURNAL . 15(1): 121-121. Nº de citas: 3
